<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02781155</url>
  </required_header>
  <id_info>
    <org_study_id>RD2015-04</org_study_id>
    <nct_id>NCT02781155</nct_id>
  </id_info>
  <brief_title>Limiting Chemotherapy Side Effects by Using Moxa</brief_title>
  <official_title>Using Daily Self-administered Indirect Moxibustion to Zusanli St-36 to Reduce Chemotherapy Induced Pancytopenia: a Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>East and North Hertfordshire NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Acupuncture Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>East and North Hertfordshire NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates whether it is feasible to teach cancer patients undergoing
      chemotherapy to self-administer daily moxibustion to reduce chemotherapy side effects.
      Moxibustion is a therapy used in traditional Chinese medicine that uses heat.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemotherapy drugs are used to treat cancer cells. However, they can also affect bone marrow
      and reduce the ability to make certain types of blood cells. Low white blood cell counts can
      leave patients vulnerable to infection. Low red blood cell counts can lead to anaemia and
      feelings of fatigue and weakness. Low platelet counts can lead to bruising and bleeding.
      Blood counts are therefore monitored. If they fall too low, the dose of chemotherapy may be
      reduced or the time between doses extended. This may affect survival as well as quality of
      life.

      Research studies in China and the West suggest that moxibustion applied by a practitioner can
      improve blood counts and immunity, and reduce side effects of chemotherapy. Moxibustion (also
      called moxa) is a form of traditional Chinese medicine that uses heat to stimulate
      acupuncture points. This heat comes from a smouldering herb called mugwort, that is rolled
      into a cigar shape to gently warm the point. Many patients regard this as a pleasant,
      relaxing experience.

      The researchers will teach patients to self-administer moxa to an acupuncture point just
      below the knee. This is a feasibility study to see if patients are willing and able to
      self-administer moxa daily throughout chemotherapy. Patients will keep a moxa diary to record
      their activity. The researchers will also use a questionnaire to assess whether patients see
      themselves as active managers of their health. This may help the researchers to screen
      suitable patients in future studies.

      The researchers will also monitor blood counts, any delays or dose reductions to the
      chemotherapy, and any chemotherapy side effects. Participants will complete quality of life
      questionnaires at intervals during and after their chemotherapy.

      If results are favourable, they will be used to design a randomised controlled trial
      comparing daily moxibustion with a &quot;no treatment&quot; control arm.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to moxa regimen assessed by Daily Moxa Diary</measure>
    <time_frame>21 days after last chemotherapy cycle</time_frame>
    <description>The primary aim of this study is to assess the feasibility of teaching cancer patients undergoing chemotherapy in the National Health Service (NHS) to self-administer daily indirect moxibustion to St 36 Zusanli, according to a protocol that begins ideally 7 to 10 days prior to the first chemotherapy cycle and continues until 21 days after the final chemotherapy cycle. Participants will complete a Daily Moxa Diary to record their adherence to the daily protocol. They will be asked also to log any days they miss, and give reasons why.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood counts, specifically white blood cells, neutrophils, haemoglobin, and platelets</measure>
    <time_frame>Throughout chemotherapy, on 1st day of each cycle, according to chemotherapy schedule. This is usually fortnightly for colorectal (Days 1, 15, 19, 43, 57, 71, 85, 99) and 3-weekly for breast and gynaecologic cancers (Days 1, 22, 43, 64, 85, 106)</time_frame>
    <description>Blood counts will be collected from the participants' medical notes to monitor incidents of neutropenia, anaemia, or thrombocytopenia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation to planned chemotherapy schedule</measure>
    <time_frame>Throughout chemotherapy, on 1st day of each cycle, according to chemotherapy schedule. This is usually fortnightly for colorectal (Days 1, 15, 19, 43, 57, 71, 85, 99) and 3-weekly for breast and gynaecologic cancers (Days 1, 22, 43, 64, 85, 106)</time_frame>
    <description>Any delays in chemotherapy schedule and the reasons why will be collected from the participants' medical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy related toxicities</measure>
    <time_frame>Throughout chemotherapy, on 1st day of each cycle, according to chemotherapy schedule. This is usually fortnightly for colorectal (Days 1, 15, 19, 43, 57, 71, 85, 99) and 3-weekly for breast and gynaecologic cancers (Days 1, 22, 43, 64, 85, 106)</time_frame>
    <description>Data will be collected from the participants' medical records, specifically the Common Terminology Criteria for Adverse Events (CTCAE), which is the standard form used in the Chemotherapy Suite to record information about any toxicities experienced by the patient resulting from chemotherapy (such as fatigue, vomiting, etc)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life (HRQOL)</measure>
    <time_frame>At Baseline, cycles 2, 3, and 6 (or final cycle), and one month after final cycle: typically Days 15, 29, 71, 127 for colorectal; Days 22, 43, 106, 134 for breast and gynaecological cancers</time_frame>
    <description>The study will seek to identify changes in quality of life, to help with hypothesis generation for future studies. Validated questionnaires from the Functional Assessment for Cancer Therapy (FACT) will be used, including:
FACT-G: a 27 item compilation of general questions covering physical, social/family, emotional and functional wellbeing; FACT-N: a 19-item neutropenia subscale designed to capture symptoms and impact on HRQOL related to neutropenia; FACT-An - a 20-item questionnaire assessing fatigue and anaemia-related concerns in people with cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient self-management</measure>
    <time_frame>At Baseline, cycle 3, and one month after final cycle: typically Days 29 and 127 for colorectal; Days 43 and 134 for breast and gynaecological cancers</time_frame>
    <description>Patients with a high level of activation are likely to engage in positive health behaviours and participate in managing their health conditions more effectively. The Patient Activation Measure (PAM) will be used to explore whether it is possible to identify patients who will be most likely to follow a daily healthcare regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by all incidents including allergies, burns, and other accidents</measure>
    <time_frame>Through study completion, spanning 16 to 28 weeks depending on chemotherapy regimen</time_frame>
    <description>The safety of moxibustion is under-reported in the literature. The researchers will monitor and record all incidents affecting safety, including allergies, burns, and other accidents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidents of additional interventions administered as prophylaxis or therapy to maintain or improve blood counts</measure>
    <time_frame>Through study completion, spanning 16 to 28 weeks depending on chemotherapy regimen</time_frame>
    <description>The researchers will record whether participants are taking or having therapies that affect blood cell counts, such as steroids, iron supplements and other dietary supplements as prophylaxis, or blood and platelet transfusions to improve low blood counts.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Genital Neoplasms, Female</condition>
  <condition>Toxicity Due to Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Self administration of moxibustion</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will be taught to self administer moxibustion to the acupuncture point Zusanli St-36, and apply it daily throughout their chemotherapy treatments</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Moxibustion</intervention_name>
    <description>Participants are taught to self administer moxibustion to acupuncture point Zusanli St-36 daily throughout the course of their chemotherapy</description>
    <arm_group_label>Self administration of moxibustion</arm_group_label>
    <other_name>Moxa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  with breast, gynaecologic, or colorectal cancer who are prescribed radical or adjuvant
             chemotherapy in the early disease setting, or first or second line chemotherapy is in
             the metastatic setting

          -  about to commence a course of chemotherapy for which granulocyte-colony stimulating
             factor (G-CSF) is not routinely indicated

          -  with a life expectancy of more than six months

          -  with blood cell counts within the normal range

          -  with calculated creatinine levels of â‰¥ 50ml/min

          -  English speaking

          -  able to understand instructions for self-administration of moxibustion and carry out
             the procedure

          -  able to give informed consent

        Exclusion Criteria:

          -  having a haematological cancer diagnosis

          -  prescribed a chemotherapy regimen for which G-CSF is indicated

          -  having third or fourth line chemotherapy

          -  having metastatic bone cancer

          -  who have concomitant severe medical problems preventing participation

          -  with cognitive impairment that would impact participant's ability to safely administer
             self-moxibustion

          -  having renal dysfunction

          -  with lymphedema in the lower body.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverley A de Valois, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lynda Jackson Macmillan Centre, Mount Vernon Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clare Scarlett, BA (Hons)</last_name>
    <phone>+44 203 826 2561</phone>
    <email>clare.scarlett1@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beverley A de Valois, PhD</last_name>
    <phone>+44 203 826 2556</phone>
    <email>beverley.devalois@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre</name>
      <address>
        <city>Northwood</city>
        <state>Middlesex</state>
        <zip>HS6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clare Scarlett, BA (Hons)</last_name>
      <phone>+44 203 826 2561</phone>
      <email>clare.scarlett1@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Beverley A de Valois, PhD</last_name>
      <phone>+44 203 826 2556</phone>
      <email>beverley.devalois@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Beverley A de Valois, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2016</study_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>East and North Hertfordshire NHS Trust</investigator_affiliation>
    <investigator_full_name>Beverley de Valois PhD LicAc FBAcC</investigator_full_name>
    <investigator_title>Research Acupuncturist</investigator_title>
  </responsible_party>
  <keyword>Health related quality of life</keyword>
  <keyword>Moxibustion</keyword>
  <keyword>Cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Neutropenia</keyword>
  <keyword>Anaemia</keyword>
  <keyword>Thrombocytopenia</keyword>
  <keyword>Self management</keyword>
  <keyword>Wellbeing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Genital Neoplasms, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

